Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Engelhardt

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Journal of the Royal Society, Interface|June 16, 2017
A Bayesian approach to estimating hidden variables as well as missing and wrong molecular interactions in ordinary differential equation-based mathematical modelsBenjamin Engelhardt, Maik Kschischo, Holger Fröhlich
Scientific Reports|February 12, 2016
Learning (from) the errors of a systems biology modelBenjamin Engelhardt, Holger Frőhlich, Maik Kschischo
Journal of Clinical Pharmacology|March 11, 2023
Use of Clinical Trial Simulations to Compare the Performance of Different Approaches for Population Analyses of Pediatric Pharmacokinetic DataZaid Temrikar, Elena Muensterman, Benjamin Engelhardt, et al.
Bioinformatics (Oxford, England)|September 15, 2020
SEEDS: data driven inference of structural model errors and unknown inputs for dynamic systems biologyTobias Newmiwaka, Benjamin Engelhardt, Philipp Wendland, et al.
Mathematical Medicine and Biology : a Journal of the IMA|May 16, 2017
Modelling and mathematical analysis of the M$_{2}$ receptor-dependent joint signalling and secondary messenger network in CHO cellsBenjamin Engelhardt, Janine Holze, Christina Elliott, et al.
Clinical and Translational Science|August 31, 2021
Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trialsElena Muensterman, Benjamin Engelhardt, Sathej Gopalakrishnan, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 10, 2024
Semi-mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and AzacitidineNeha Thakre, Corinna Maier, Jiuhong Zha, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 26, 2026
Population Pharmacokinetics and Exposure-Response Analyses for Telisotuzumab Vedotin in Patients With c-Met Protein Overexpressing TumorsHeiko Babel, Priya Brunsdon, Benjamin Engelhardt, et al.
Investigational New Drugs|October 10, 2024
Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patientsMohamed Ali Badawi, Benjamin Engelhardt, Edyta Dobkowska, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 10, 2026
Semi-Mechanistic PK/PD Modeling of Platelets and Spleen Volume With Navitoclax in Combination With Ruxolitinib in Patients With MyelofibrosisAkshanth R Polepally, Aline Goebel, Maulik Patel, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of the Royal Society, Interface|June 16, 2017
A Bayesian approach to estimating hidden variables as well as missing and wrong molecular interactions in ordinary differential equation-based mathematical modelsBenjamin Engelhardt, Maik Kschischo, Holger Fröhlich
Scientific Reports|February 12, 2016
Learning (from) the errors of a systems biology modelBenjamin Engelhardt, Holger Frőhlich, Maik Kschischo
Journal of Clinical Pharmacology|March 11, 2023
Use of Clinical Trial Simulations to Compare the Performance of Different Approaches for Population Analyses of Pediatric Pharmacokinetic DataZaid Temrikar, Elena Muensterman, Benjamin Engelhardt, et al.
Bioinformatics (Oxford, England)|September 15, 2020
SEEDS: data driven inference of structural model errors and unknown inputs for dynamic systems biologyTobias Newmiwaka, Benjamin Engelhardt, Philipp Wendland, et al.
Mathematical Medicine and Biology : a Journal of the IMA|May 16, 2017
Modelling and mathematical analysis of the M$_{2}$ receptor-dependent joint signalling and secondary messenger network in CHO cellsBenjamin Engelhardt, Janine Holze, Christina Elliott, et al.
Clinical and Translational Science|August 31, 2021
Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trialsElena Muensterman, Benjamin Engelhardt, Sathej Gopalakrishnan, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 10, 2024
Semi-mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and AzacitidineNeha Thakre, Corinna Maier, Jiuhong Zha, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 26, 2026
Population Pharmacokinetics and Exposure-Response Analyses for Telisotuzumab Vedotin in Patients With c-Met Protein Overexpressing TumorsHeiko Babel, Priya Brunsdon, Benjamin Engelhardt, et al.
Investigational New Drugs|October 10, 2024
Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patientsMohamed Ali Badawi, Benjamin Engelhardt, Edyta Dobkowska, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 10, 2026
Semi-Mechanistic PK/PD Modeling of Platelets and Spleen Volume With Navitoclax in Combination With Ruxolitinib in Patients With MyelofibrosisAkshanth R Polepally, Aline Goebel, Maulik Patel, et al.
Pageof 2